

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**Single Technology Appraisal**

**Zuranolone for treating severe postnatal depression ID6431**

**Provisional Stakeholder List**

<b>Provisional Consultees</b>	<b>Provisional Commentators (no right to submit or appeal)</b>
<p><u>Company</u></p> <ul style="list-style-type: none"> <li>• Biogen (Zuranolone)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Action on Postpartum Psychosis</li> <li>• Association for Post Natal Illness</li> <li>• Association of Mental Health Providers</li> <li>• Bipolar UK</li> <li>• C.A.L.M</li> <li>• Child Bereavement UK</li> <li>• Depression UK</li> <li>• Maternal Mental Health Alliance</li> <li>• Mental Health Foundation</li> <li>• Mental Health Matters</li> <li>• MIND</li> <li>• National Childbirth Trust</li> <li>• PANDAS</li> <li>• PAPHYRUS</li> <li>• Race Equality Foundation</li> <li>• Rethink</li> <li>• Sands - Stillbirth and neonatal death charity</li> <li>• SANE</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> <li>• The Matthew Trust</li> <li>• WISH - A Voice for women's mental health</li> </ul> <p><u>Healthcare professional groups</u></p> <ul style="list-style-type: none"> <li>• British Association for Counselling and Psychotherapy</li> <li>• British Association for Psychopharmacology</li> <li>• British Association of Behavioural and Cognitive Psychotherapies</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• All Wales Therapeutics and Toxicology Centre</li> <li>• Allied Health Professionals Federation</li> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Care Council for Wales</li> <li>• Care Quality Commission</li> <li>• Department of Health - Northern Ireland</li> <li>• Gofal</li> <li>• Hafal</li> <li>• Healthcare Improvement Scotland</li> <li>• Medicines and Healthcare products Regulatory Agency</li> <li>• MIND Cymru</li> <li>• National Association of Primary Care</li> <li>• National Pharmacy Association</li> <li>• NHS Confederation</li> <li>• Scottish Medicines Consortium</li> <li>• Social Care Institute for Excellence</li> <li>• Welsh Government</li> <li>• Welsh Health Specialised Services Committee</li> </ul> <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> <li>• Accord Healthcare (amitriptyline, citalopram, duloxetine, escitalopram, imipramine, lofepramine, mirtazapine, fluoxetine, paroxetine, quetiapine, sertraline and venlafaxine)</li> <li>• Amneal Pharma Europe (duloxetine, paroxetine)</li> <li>• Aristo Pharma (quetiapine)</li> <li>• AstraZeneca (quetiapine)</li> <li>• Aurobindo Pharma (citalopram, duloxetine, escitalopram, fluoxetine,</li> </ul>

Provisional stakeholder list for the evaluation of zuranolone for treating severe postnatal depression ID6431

Issue date: September 2024

© National Institute for Health and Care Excellence 2024. All rights reserved. 1 of 4

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> <li>• British Association of Occupational Therapists and College of Occupational Therapists</li> <li>• British Association of Social Workers</li> <li>• British Geriatrics Society</li> <li>• British Neuropsychiatry Association</li> <li>• British Psychoanalytic Council</li> <li>• British Psychological Society</li> <li>• British Psychotherapy Foundation</li> <li>• College of Mental Health Pharmacy</li> <li>• Counsellors and Psychotherapists in Primary Care</li> <li>• Health and Care Professions Council</li> <li>• Mental Health Nurses Association</li> <li>• Primary Care Mental Health Education</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> <li>• Royal College of Psychiatrists</li> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicine</li> <li>• UK Clinical Pharmacy Association</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health and Social Care</li> <li>• NHS England</li> </ul>	<p>mirtazapine, paroxetine, quetiapine, sertraline and venlafaxine)</p> <ul style="list-style-type: none"> <li>• Chiesi (venlafaxine)</li> <li>• Consilient Health (duloxetine, escitalopram, quetiapine and venlafaxine)</li> <li>• Creo Pharma (lofepramine and trazodone)</li> <li>• Dexcel Pharma (venlafaxine)</li> <li>• Dr Reddys Labs (duloxetine, fluoxetine and sertraline)</li> <li>• Fontus heath (quetiapine)</li> <li>• GlaxoSmithKline (paroxetine)</li> <li>• HBS Healthcare (duloxetine)</li> <li>• King Pharmaceuticals (nortriptyline)</li> <li>• Kyowa Kirin (phenelzine)</li> <li>• Lilly UK (duloxetine and fluoxetine)</li> <li>• Lundbeck (citalopram, escitalopram, vortioxetine)</li> <li>• Lupin (sertraline)</li> <li>• Marlborough (doxepin)</li> <li>• Merck Sharp &amp; Dohme (mirtazapine)</li> <li>• Mylan (citalopram, clomipramine, escitalopram, fluoxetine, fluvoxamine, lofepramine, mianserin, mirtazapine, paroxetine, quetiapine, trazodone and venlafaxine)</li> <li>• Par Laboratories Europe (fluoxetine)</li> <li>• Pfizer (reboxetine, sertraline and venlafaxine)</li> <li>• Rivopharm (citalopram, trazodone)</li> <li>• Sandoz (citalopram, paroxetine and quetiapine)</li> <li>• Servier (agomelatine)</li> <li>• Sun Pharmaceuticals (sertraline and venlafaxine)</li> <li>• Teva UK (amitriptyline, citalopram, clomipramine, fluoxetine, fluvoxamine, imipramine, lofepramine, mianserin, mirtazapine, paroxetine, sertraline, trazodone and venlafaxine)</li> <li>• Wockhardt (amitriptyline, fluoxetine, fluvoxamine, mirtazapine and venlafaxine)</li> </ul>

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
	<ul style="list-style-type: none"> <li>• Zentiva (citalopram, duloxetine, escitalopram, quetiapine, trazodone and trimipramine)</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• Campbell Collaboration Social Welfare Group</li> <li>• Careif</li> <li>• Cochrane Depression Anxiety and Neurosis Group</li> <li>• Critical Psychiatry Network</li> <li>• Genomics England</li> <li>• Health Services Research Unit, Department of Public Health, University of Oxford</li> <li>• Institute of Psychiatry</li> <li>• Joseph Rowntree Foundation</li> <li>• MRC Clinical Trials Unit</li> <li>• National Institute for Health Research</li> <li>• National Primary Care Research &amp; Development Centre</li> </ul> <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> <li>• Public Health Wales</li> <li>• UK Health Security Agency</li> </ul>

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

**Definitions:**

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

### Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.